GSK has reported positive interim results from its Phase II trial of mRNA-based multivalent influenza vaccine candidate, ...

Drug maker GSK (GSK) agreed to pay up to $1.56 billion for the rights to develop, manufacture, and market COVID-19 and influenza vaccines being worked on in collaboration with German biotechnology ...

GSK’s influenza vaccine, Fluarix Quadrivalent, has been approved by the US FDA for the immunisation of adults and children aged three years and older to help prevent disease caused by seasonal ...

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.

The shortage of certain types of influenza vaccines could end as early as next month with the arrival of new stock, says ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

Malaysia’s health ministry said there is no rising trend of influenza cases in Malaysia. Read more at straitstimes.com.

The European Commission has just approved the prepandemic vaccine Prepandrix from GlaxoSmithKline ... application for its own prepandemic flu vaccine, Aflunov. The European Medicines Agency's ...

American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...

The doctor recommended getting updated flu vaccines annually to lower the risk of contracting the virus and be protected from ...

influenza, malaria, and others. In 2022, GSK’s 12 manufacturing sites in eight countries produced and delivered more than 500 million vaccine doses—one and a half million vaccine doses daily.